ExThera Medical Creates Scientific Advisory Board to Advance the Organization’s Global Clinical Trial Program
March 11, 2019

Martinez, Calif. – March 11, 2019 ExThera Medical Corporation (ExThera) today announced the formation of its Scientific Advisory Board (SAB). Led by chairman Lakhmir (Mink) Chawla, MD, current Chief Medical Officer of La Jolla Pharmaceutical Company, the SAB will include several esteemed medical professionals from both the U.S. and Germany. Professor Dr. Herwig Gerlach, Director of the Clinic for Anesthesiology, Critical Care Medicine and Pain Management at Vivantes Klinikum Neukoelln Berlin Germany, and Stuart Goldstein, MD, Director of the Center for Acute Care Nephrology at Cincinnati Children’s Hospital Medical Center, will join the ExThera SAB immediately. ExThera, an early-stage device company in the San Francisco Bay Area, is a developer of novel therapies for reducing bacteria and viruses in blood.

As ExThera innovates to improve the treatment of bloodstream infections and sepsis globally, the three SAB appointees bring comprehensive medical and research expertise to the company, including direction of ExThera’s U.S. and European clinical trial programs.

Prior to joining the board, Dr. Chawla was a Professor of Medicine at the George Washington University Medical Center in Washington, D.C. where he directed research efforts for the Division of Critical Care Medicine. He previously headed the Division of Intensive Care Medicine at the Washington DC Veterans Affairs Medical Center, and currently serves as a Clinical Professor of Medicine at the University of California, San Diego Medical Center. With a focus on critical care and nephrology, Dr. Chawla has led and supported several grants and research projects centered on acute kidney injury, renal disease, extra-corporeal therapies, shock, and sepsis.

Professor Gerlach brings expertise in anesthesiology and critical care medicine as a board-certified physician and professor. A widely published researcher, he has investigated issues pertaining to intensive care, critical care and emergency medicine, post-operative care, and the treatment of sepsis, which are highly relevant to ExThera’s mission of developing new therapies for the treatment of bloodstream infections. In addition to his several roles throughout Germany, Prof. Dr. Gerlach also previously served as a research fellow at Columbia University in New York. He previously served as President of the German Sepsis Society and is now Vice President.

Dr. Goldstein contributes expertise in nephrology and brings to the board a unique perspective from his background in pediatric care. In addition to his current role at Cincinnati Children’s Hospital Medical Center, he holds a faculty position as a professor of pediatrics for the University of Cincinnati School of Medicine. Dr. Goldstein has also led and contributed research support for several research investigations focused on device therapies, including those with emphasis on renal failure and end-stage renal disease, for various institutions.

“I am delighted to be working with ExThera and Professors Gerlach and Goldstein. Despite progress in the treatment of many infectious diseases there remain many pathogens for which there are no effective anti-microbials. The ExThera technology brings cutting-edge material science to the bedside allowing clinicians to treat bacterial and viral diseases that do not have adequate treatments available. It is an exciting opportunity to bring a new weapon to fight these infectious diseases.” said Lakhmir ‘Mink’ Chawla, MD, Chairman of the SAB.

About ExThera Medical
Based in Martinez, California, and in Vaals, The Netherlands, ExThera is a privately held medical device company developing innovative, single-use blood filters capable of capturing and removing a broad range of bacteria, viruses, parasites, toxins or other harmful substances from whole blood. The company develops therapeutic products to treat patients in the hospital or clinic, during epidemics, or on the battlefield. Led by an accomplished management team with extensive experience in blood-contacting devices and biomaterials, the company has strong patent protection and a growing body of data from independent laboratory studies, from its participation in DARPA’s Dialysis-Like Therapeutics program and from a successful EU clinical trial. For more information, visit www.extheramedical.com.

Disclaimer: All information contained in this news release derives from plausible reliable sources, which, however, have not been independently examined. There is no warranty, confirmation or guarantee, and no responsibility or liability is taken concerning correctness or completeness. As far as it is allowed by the relevant law, no liability whatsoever is taken on for any direct or indirect loss caused by the deployment of this news release or its contents. This communication includes forward-looking statements regarding events, trends and business prospects that may affect our future operating results and financial position. Such statements are subject to risks and uncertainties that could cause our actual results and financial position to differ materially. The investment and/or the revenues that arise from it can rise or fall. A total loss is possible. Persons who are in possession of this news release are requested to obtain information concerning possible legal limitations and to observe them accordingly. We assume no responsibility to update or revise any forward-looking statements contained in this news release to reflect events, trends, or circumstances after the date of this news release.

Caution: The Seraph® Microbind® Affinity Blood Filter is currently undergoing clinical evaluation and is not available for commercial sale.

MM0006 Rev B